We are live on ! Find out more
SONN

Sonnet BioTherapeutics
SONN

Delisted

SONN was delisted on the 2nd of December, 2025.

Back to rankings

0 hedge funds and large institutions have $532K invested in Sonnet BioTherapeutics in 2016 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% less capital invested

Capital invested by funds: $1.09M → $532K (-$556K)

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
TDC
Thompson Davis & Co
Virginia
-$414K
2
BIM
BlackRock Investment Management
Delaware
-$3K
3
Morgan Stanley
Morgan Stanley
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
TDC
1
Thompson Davis & Co
Virginia
$135K -$414K -1 Closed
Vanguard Group
2
Vanguard Group
Pennsylvania
$94K – – –
IC
3
Intersect Capital
California
$53K – – –
BIT
4
BlackRock Institutional Trust
California
$44K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$39K – – –
GHAM
6
Gilman Hill Asset Management
Connecticut
$26K – – –
Stifel Financial
7
Stifel Financial
Missouri
$25K – – –
CDH
8
Charles D. Hyman
$19K – – –
Bank of America
9
Bank of America
North Carolina
$18K – – –
EVC
10
Eidelman Virant Capital
Missouri
$16K – – –
Citadel Advisors
11
Citadel Advisors
Florida
$15K – – –
SI
12
SII Investments
Wisconsin
$13K – – –
CL
13
CSS LLC
Illinois
$10K – – –
VKH
14
Virtu KCG Holdings
New York
$9K – – –
Northern Trust
15
Northern Trust
Illinois
$8K – – –
First Manhattan
16
First Manhattan
New York
$3K – – –
Barclays
17
Barclays
United Kingdom
$2K – – –
BFA
18
BlackRock Fund Advisors
California
$2K – – –
IA
19
IFP Advisors
Florida
$1K – – –
BIM
20
BlackRock Investment Management
Delaware
– -$3K – –
Morgan Stanley
21
Morgan Stanley
New York
– -$1K – –

SONN Hedge Fund Activity: Q2 2016 in Review

0 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q2 2016, worth a combined $532K — down 51% from $1.09M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of SONN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Thompson Davis & Co, exiting entirely with an estimated $414K sold.

  • 0 institutional investors held Sonnet BioTherapeutics (SONN) as of Q2 2016, down from 1 in Q1 2016.
  • Funds reported $532K of Sonnet BioTherapeutics stock for Q2 2016, down 51% quarter-over-quarter.
  • 0 funds opened new Sonnet BioTherapeutics positions in Q2 2016 and 1 closed out, a net change of -1 holder.
  • The largest Sonnet BioTherapeutics seller in Q2 2016 was Thompson Davis & Co, an estimated $414K sold.

Based on aggregated 13F filings for Q2 2016.